PT  - JOURNAL ARTICLE
AU  - BY SOO YONG LEE
AU  - DAE GEUN JEON
AU  - WAN HYUNG CHO
AU  - WON SEOK SONG
AU  - MOON BO KIM
AU  - JONG HOON PARK
TI  - Preliminary Study of Chemosenstivity Tests in Osteosarcoma Using a Histoculture Drug Response Assay
DP  - 2006 Jul 01
TA  - Anticancer Research
PG  - 2929--2932
VI  - 26
IP  - 4B
4099  - http://ar.iiarjournals.org/content/26/4B/2929.short
4100  - http://ar.iiarjournals.org/content/26/4B/2929.full
SO  - Anticancer Res2006 Jul 01; 26
AB  - Background: The clinical efficacy of chemotherapy is strongly correlated with the histoculture drug response assay (HDRA) in various types of cancers. However, there have been no previous reports on its use in osteosarcoma. Materials and Methods: Thirty-six fresh samples of human osteosarcoma were evaluated by the HDRA method in order to determine its possible usefulness in the treatment of this cancer. All the materials were obtained either during biopsy or surgical excision at our hospital, between January 2003 and October 2005. Results: A significant inhibition rate in primary biopsies was observed with Adriamycin (ADM) (47.3±15.3%); Cisplatin (CDDP) (36.3±22.3%); and Carboplatin (CBP) (50.5±23.3%); treatment. ADM and CBP demonstrated a statistically significant increase in inhibition rates compared to the other drugs. Conclusion: Even though the HDRA method has many limitations, it might be a feasible and useful technique for selecting and predicting the efficacy of anticancer drugs for osteosarcoma patients. Copyright© 2006 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved